ReviewMicroorganisms2025
Neutralizing Antibodies vs. Viruses: Interacting Mechanisms and Escape Tactics.
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Structure-Function Engineering of Hydrogel-MOF Polymer Composites for Regenerative Wound Dressings with Emerging Antiviral Biointerface Functions.Gels (Basel, Switzerland) · 2026Review
- Efficacy of an Fc-silent antibody targeting the apical domain of human transferrin receptor 1 in transgenic mouse models of Junín virus infection.Antiviral research · 2026Article
- Selected Cannabinoids, Cannabimimetic Agents andPharmaceuticals (Basel, Switzerland) · 2026Review
- Skin Deep: Uncovering the Early Events of Crimean-Congo Hemorrhagic Fever Virus at the Tick-Host-Virus Interface.Viruses · 2026Review
- Development and clinical application of recombinant polyclonal antibodies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Virus-neutralizing antibodies (VNAs) serve as critical components of host immune defense, countering viral infections by specifically recognizing epitopes on viral surface antigens to block viral entry and replication. This review elucidates the functional mechanisms of VNAs, with a focus on the dynamic interactions between the Fab region and viral epitopes, including steric hindrance and conformational locking, as well as the effector functions mediated by the Fc segment. Furthermore, we dissect diverse viral evasion strategies against neutralization that have emerged in recent studies, encompassing antigenic drift/shift, glycan shielding, epitope occlusion, antibody-dependent enhancement, and mutation accumulation under population immune pressure. Integrating structural biology insights with clinical evidence, we analyze challenges in developing broadly neutralizing antibodies and highlight innovative technological approaches. Our synthesis aims to establish a theoretical framework for the rational design and clinical translation of next-generation VNAs, thereby advancing novel strategies for antiviral therapeutics development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.